Kalaris Therapeutics
KLRS
32 hedge funds and large institutions have $76.4M invested in Kalaris Therapeutics in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
114% more capital invested
Capital invested by funds: $35.7M → $76.4M (+$40.8M)
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
7% more funds holding
Funds holding: 30 → 32 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.75% less ownership
Funds ownership: 71.45% → 70.7% (-0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$797K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$242K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$190K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$132K |
| 5 |
FCA
Fortis Capital Advisors
Prairie Village,
Kansas
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$961K |
| 2 |
GS
Gilead Sciences
Foster City,
California
|
-$848K |
| 3 |
Millennium Management
New York
|
-$96.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$64.7K |
| 5 |
Squarepoint
New York
|
-$62.5K |
KLRS Hedge Fund Activity: Q3 2025 in Review
32 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2025, worth a combined $76.4M — up 114% from $35.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new KLRS positions and 6 closed out — a net gain of 2 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $797K. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $961K sold.
- 32 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2025, up from 30 in Q2 2025.
- Funds reported $76.4M of Kalaris Therapeutics stock for Q3 2025, up 114% quarter-over-quarter.
- 8 funds opened new Kalaris Therapeutics positions in Q3 2025 and 6 closed out, a net change of +2 holders.
- The largest Kalaris Therapeutics buyer in Q3 2025 was Woodline Partners, an estimated $797K added.
- The largest Kalaris Therapeutics seller in Q3 2025 was Octagon Capital Advisors, an estimated $961K sold.
Based on aggregated 13F filings for Q3 2025.